Musaffa Logo

Our certifications

Independent proof that every stock and portfolio meets halal standards.

How we screen every stock
METHODOLOGY

How we screen every stock

Our 5-step halal methodology, in 90 seconds.

AGRX Shariah Compliance

Screening Methodology: AAOIFI

NOT HALAL

Last Updated: July 27, 2024

Report Source: 2024 1st Quarter Report

Analyst's Ratings for Agile Therapeutics Inc (AGRX)

Based on 7 analysts giving stock ratings to Agile Therapeutics Inc in the past 3 months

Strong
Sell
SellHoldBuyStrong
Buy
Strong Buy
29
Buy
57
Hold
14
Sell
0
Strong Sell
0
Agile Therapeutics Inc

Agile Therapeutics Inc. Stock Analysis AGRX

United States Health Care Nano Cap Report:
Agile Therapeutics, Inc. is a healthcare company, which engages in the development and commercialization of transdermal patches. The company is headquartered in Princeton, New Jersey and currently employs 19 full-time employees. Its product and product candidates are designed to provide women with contraceptive options that offer freedom from taking a daily pill, without committing to a longer-acting method. Its initial product, Twirla, (levonorgestrel and ethinyl estradiol), a transdermal system, is a non-daily prescription contraceptive. Twirla is based on its proprietary transdermal patch technology, called Skinfusion, which is designed to allow drug delivery through the skin. Twirla (levonorgestrel and ethinyl estradiol) transdermal system is a once-weekly combined hormonal contraceptive (CHC) patch that contains the active ingredients levonorgestrel (LNG), a type of progestin, and ethinyl estradiol (EE), a type of estrogen. Its potential product pipeline consists of two types of product candidates: a progestin-only (P-only) contraceptive patch and potential Twirla line extensions.
Read More

Agile Therapeutics Inc (AGRX) Chart

Key Statistics of Agile Therapeutics Inc (AGRX)

Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.

Today's Range

$1.51$1.52

Today's Open

$1.51

Volume

120.94K

P/E Ratio (TTM)

-

52 Week Range

$1.65$16.00

Market Cap

10.43M

Avg. Volume

67.04K

Dividend Yield

-

Financial Metrics & Statements of Agile Therapeutics Inc (AGRX)

FAQ's for Agile Therapeutics Inc (AGRX)

  • According to Musaffa’s Shariah screening methodology, Agile Therapeutics Inc (AGRX) is currently classified as NOT HALAL as of July 2024. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.
  • A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Agile Therapeutics Inc using these criteria to determine its compliance status.
  • Muslim investors may consider investing in Agile Therapeutics Inc if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
  • Musaffa determines the Shariah status of Agile Therapeutics Inc by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
  • The Shariah compliance status of Agile Therapeutics Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.
  • Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
  • You can check the latest Shariah compliance status of Agile Therapeutics Inc on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.

Disclaimer

The content provided on this website is intended solely for informational and educational purposes. Musaffa is a technology, data, education, and research company. We are not licensed financial service provider by the authorized relevant financial service regulator in India or any other regulatory government body, and we do not offer or facilitate any trading, brokerage, investment, or financial advisory services. We do not deliberately target an audience seeking financial services.

By accessing this website, you acknowledge and confirm that you are seeking information relating to Musaffa of your own accord, and that there has been no form of solicitation, advertisement, or inducement by Musaffa or its members. Musaffa shall not be liable for the consequences of any action taken by relying on the material or information provided on this website. The contents of this website are the intellectual property of Musaffa.